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CD19 chimeric antigen receptor (CAR) T cell therapy
has shown great promise in treating human hematologi-
cal malignancies. However, the full potential of CAR
technology has not been reached in solid malignancies
and limitations exist in utilizing genetically identical
murine models to interrogate the safety and efficacy of
anti-tumor immune therapies. Canines are an outbred
population that naturally develop spontaneous disease.
Here we have established a treatment model for CAR
T cell therapy in outbred dogs with spontaneous B cell
lymphoma.
We developed a protocol to isolate, activate, and
express CAR in canine T cells. We characterized a
methodology utilizing anti-cCD3 antibody with a K562
antigen-presenting cell (APC) line that expresses human
CD32 and canine CD86 to activate canine lymphocytes.
This method yields robust (50-120x) expansion of
cCD4+ or cCD8+ T cells from normal or lymphoma-
diseased dogs.
Canine T cells were then engineered utilizing mRNA
electroporation to express a CAR targeting the B cell
antigen CD20. An anti-canine CD20 (cCD20) CAR was
selected for proof of principle studies to establish feasibil-
ity of efficient CAR expression and redirected effector
function in canine T cells from a healthy and lymphoma-
diseased dogs. The cCD20-Z CAR construct was effi-
ciently, but transiently, expressed in canine T cells after
mRNA electroporation. cCD20 CAR T cells exhibited
specific lysis and IFN-g secretion in response to cCD20+
target cells. These data indicate successful establishment
of a method to isolate, activate, and express a fully
functional CAR in canine T cells for use in adoptive
immunotherapy. These results rationalized testing of
this CAR approach in canines with advanced CD20+
malignancies.
In an IACUC approved protocol, we administered three
doses of autologous cCD20-Z RNA CAR+ T cells to a
companion canine with advanced B cell lymphoma. Treat-
ment was well-tolerated and no evidence of serious
adverse events was observed. The anti-tumor effect,
however, was transient, suggesting a need for product
optimization. Future study will establish a lenti- or retro-
viral-based method to modify canine T cells to promote
T cell persistence and durable anti-tumor effects in vivo.
In conclusion, our study establishes the methodologies
and feasibility of anti-cCD20 CAR therapy in canines with
spontaneous B cell lymphoma that may represent a future
clinical option for such companion pets. This work also
lays the foundation for study of a large, outbred animal
model that better resembles spontaneous, human malig-
nancies to allow for improved assessment for potential
toxicity risks prior to translation into human studies.
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